HealthPhoto: European Medical JournalCapivasertib Causes Hyperglycemia in 37% of Patients: Prevention and Monitoring
In the CAPItello-291 trial, 37% of patients treated with capivasertib experienced an increase in fasting glucose levels of any grade. The study highlights key steps for the prevention, monitoring, and treatment of hyperglycemia associated with capivasertib use to manage this side effect effectively.
European Medical Journal·




